On the Record · Nektar Therapeutics

Nektar Therapeutics acquisitions, on the record

The businesses Nektar Therapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Shearwater Corp. Word for word“We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively.” 10-K for 2023	acquisition	2001	—
Aerogen, Inc. Word for word“We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively.” 10-K for 2023	acquisition	2005	—
Gannet BioChem Word for word“In December 2024, we completed the sale of our manufacturing facility in Huntsville, Alabama (the Facility), and assigned our manufacturing and supply agreements to Gannet BioChem, an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners for consideration of $64.7 million in cash, net of transaction costs, and an approximate 20% equity interest at the time of close in Gannet BioChem (the Transactions).” 10-K for 2024	divestiture	December 2024	$64.7 million in cash, net of transaction costs, and an approximate 20% equity interest at the time of close in Gannet BioChem
research and development facility in India Word for word“As a result of the sale of our research and development facility in India, we have cash and investment balances in India that we intend to repatriate as part of our closure of this entity.” 10-K for 2024	divestiture	—	—
Huntsville, Alabama manufacturing facility (the Facility), sold to Gannet BioChem Word for word“On December 2, 2024, we completed the sale of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, to Gannet BioChem, an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), via an Asset Purchase Agreement (the APA), for consideration of $ 64.7 million in cash, net of transaction costs, and an approximate 20 % equity ownership at the time of close in Gannet BioChem.” 10-K for 2025	divestiture	On December 2, 2024	$ 64.7 million in cash, net of transaction costs, and an approximate 20 % equity ownership at the time of close in Gannet BioChem

Deal filings since 2016

2026-05-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-04-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-02-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-12-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2024-11-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-03-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-03-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-02-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-01-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2020-12-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-01-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-06-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-02-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-07-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-10-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-09-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-06-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Nektar Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-03-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.